Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 2, 2024PLoS ONEOpen Access

Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager

View Full Paper
Ask AI
Bookmark
Share

Authors

LELinda G EissenbergJRJulie RitcheyMRMichael P. Rettig

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Eissenberg et al. (2024) studied this question.

synapsesocial.com/papers/68e6bd41b6db64358763d93chttps://doi.org/10.1371/journal.pone.0300174
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia2025
  2. 2A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia2025
  3. 3Enhancement of CD117-targeted bispecific T-cell engagement by CD33-targeted bispecific T-cell co-stimulation in acute myeloid leukemia2026
  4. 4CD84-CD3 bispecific antibody achieves potent anti-leukemic activity with favorable safety profile in Acute Myeloid Leukemia2025
  5. 5Abstract 5394: Novel multispecific T cell engagers exploit avidity for highly selective targeting of B-myeloid mixed-phenotype acute leukemia.2026